ArticleDiscover oncology2026
A novel model based on ferroptosis-related lncRNAs for predicting prognosis and adjuvant therapy response in colon adenocarcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundColon adenocarcinoma (COAD) remains the most prevalent pathological subtype of colorectal carcinoma, yet its long-term survival outcomes remain suboptimal despite advances in clinical management. Ferroptosis is an iron-dependent regulated cell death modality that participates critically in tumor growth and development. Long noncoding RNAs (lncRNAs) are important regulators of ferroptosis pathways in cancer. Accordingly, the present study aimed to explore the prognostic value and therapeutic response of ferroptosis-related lncRNAs in COAD.
methodsFerroptosis-related lncRNAs were initially screened via co-expression analysis, then a ferroptosis-related lncRNA prognostic signature was established by univariate and multivariate Cox regression analyses. We comprehensively validated using multiple approaches, which included survival analysis, receiver operating characteristic (ROC) curve analysis and a nomogram. In addition, we analyzed the potential associations of this signature with immunotherapeutic and chemotherapy responsiveness.
resultsWe established and subjected to validation a risk signature based on seven ferroptosis-related lncRNAs (AC107308.1, ZKSCAN2-DT, LINC02381, SFTA1P, SNHG16, AL137782.1 and LINC01138). The risk model showed potential value in stratifying distinct immunotherapeutic response patterns to immunotherapy in different subgroups of COAD patients. Five candidate therapeutic agents were predicted and differential drug sensitivity profiles were observed.
conclusionsThe risk model based on ferroptosis-related lncRNAs showed favorable prognostic predictive performance for COAD and might provide a potential reference for clinical personalized adjuvant therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.